In Vivo Neuroregeneration
Leading A Revolution in Brain Repair

About Us

NeuExcell Therapeutics is an early stage biopharmaceutical company. We are developing a revolutionary brain repair technology for neurological diseases. Our mission is to cure neurodegenerative diseases and neural injuries, such as stroke, ALS, Huntington’s disease and Alzheimer’s disease, through our world-leading astrocyte-to-neuron transdifferentiation platform.

A Revolution in Brain Repair - In Situ Regeneration

Despite great investment and hope in the past decades, there is no effective therapy that can cure ALS or reverse the progression of Alzheimer's disease. Likewise, therapies that treat stroke or brain/spinal cord injury have limited and variable efficacy at the best. The fundamental problem that has not been adequately addressed is to recover a sufficient number of lost neurons to restore lost brain functions.

In neurodegenerative or acutely injured brains, neurons die while glial cells, a group of supporting cells surrounding neurons, become reactive and proliferate. Our in situ transdifferentiation technology takes the advantage of reactive and proliferative astrocytes, as a result of neuronal degeneration or injury, and converts these reactive glial cells into functional neurons with high efficiency. The newly generated neurons are fully functional and integrate into existing brain circuits, leading to functional recovery. This technology has a broad scope of applications to treat neurodegenerative diseases and neural injuries.

Our Team

Gong is the key founder of our company and serves as President and Board of Director Chair. Gong is a Willaman Chair Professor at Penn State University. He pioneered the in situ cell conversion technology for brain and spinal cord repair. This groundbreaking technology can treat a wide range of neurological disorders, including stroke, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, traumatic brain injury, spinal cord injury, and ALS. Gong has published many high-impact papers in the neuroscience field. He organized and chaired the first in situ cell conversion symposium at the 2014 Neuroscience Meeting. Gong was honored with Zenith Fellow Award by Alzheimer’s Foundation for his breakthrough work. Gong and his team have filed and obtained a series of patent applications. Gong received his BS at Fudan University and PhD at Shanghai Institute of Physiology.

Gong Chen, PhD

Board Chair and Founder

CEO, TBA

Xi joins NeuExcell in 2019 as its CFO. As COO and CFO at GENEWIZ (a global leader in genomics services), Xi led the business growth from $9M in 2009 to >$120M, from 50 full time employee to more than 1200 in US/China/Europe/Japan, resulting in a strategic sale for $450M in November 2018.  Xi also had 10 years’ corporate finance and operational experiences at Northwest Airlines and Eli Lilly.  Xi has an MBA from Duke, M.S. in Immunology from Harvard, and B.S. in Biochemistry from Peking University.

Xi Qin, MBA

Chief Financial Officer

Jie is one of the co-founders and serves as Head of Discovery of our company. Before joining NeuExcell, Jie worked at Penn State as a researcher and lab manager. Prior to Penn State, she worked at a startup biotech company Xenoport Inc. where she was part of the team building the research laboratory as one of the first employees. Jie’s research experience covers molecular biology, immunology, virology, and neurodevelopment. Jie received her BS in biochemistry at Peking University and MS in cell biology at Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.

Jie Xu

Head of Discovery